Delving into the Latest Updates on Divozilimab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

BCD-132

Target

CD20

Mechanism

CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Complement dependent cytotoxicity (CDC) effects

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [4]

Active Indication

Scleroderma, SystemicNeuromyelitis Optica

Inactive Indication

Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting

Originator Organization

Biocad CJSC

Active Organization

Biocad CJSC

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Gene Sequence

Sequence Code 524303112H

Source: *****

Sequence Code 524303114L

Source: *****

The study is a randomized, double-blind, placebo-controlled clinical study of the efficacy and safety of divozilimab in patients with systemic scleroderma.The study will enroll adult patients of both sexes diagnosed with active systemic scleroderma according to the ACR/EULAR 2013 criteria with a modified Rodnan skin score (mRSS) of 10 to 20. In patients having signs of ILD, the Forced Vital Capacity (FVC) should be at least 40 % of the due value. Subjects will be randomized to divozilimab or placebo group.

Start Date26 Dec 2022

Sponsor / Collaborator

Biocad CJSC

NCT05730699 / RecruitingPhase 3

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders

The goal of this clinical trial is to study the efficacy and safety of BCD-132 (divozilimab) in subjects with neuromyelitis optica spectrum disorders (NMOSD).

Start Date12 Dec 2022

Sponsor / Collaborator

Biocad CJSC

100 Clinical Results associated with Divozilimab

Login to view more data

100 Translational Medicine associated with Divozilimab

Login to view more data

100 Patents (Medical) associated with Divozilimab

Login to view more data

5

Literatures (Medical) associated with Divozilimab

01 Jan 2023·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

[Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS].

Article

Author: Bolsun, D D ; Kotov, S V ; Greshnova, I V ; Mishin, G N ; Smagina, I V ; Trushnikova, T N ; Linkova, Yu N ; Trinitatsky, Yu V ; Eremeeva, A V ; Goncharova, Z A ; Pokhabov, D V ; Shchur, S G ; Zaslavsky, L G ; Chefranova, J Yu ; Boyko, A N ; Poverennova, I Ye ; Parshina, E V ; Zinkina-Orikhan, A V ; Prakhova, L N ; Alifirova, V M ; Malkova, N A ; Khabirov, F A ; Totolyan, N A ; Lukashevich, I G ; Dudin, V A ; Sivertseva, S A

01 Jan 2023·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

[Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2].

Article

Author: Goncharova, Z A ; Kotov, S V ; Greshnova, I V ; Mishin, G N ; Zaslavsky, L G ; Boyko, A N ; Parshina, E V ; Poverennova, I Ye ; Linkova, Yu N ; Bolsun, D D ; Artemyeva, A V ; Prakhova, L N ; Alifirova, V M ; Zinkina-Orikhan, A V ; Malkova, N A ; Smagina, I V ; Trushnikova, T N ; Khabirov, F A ; Trinitatsky, Yu V ; Totolyan, N A ; Lukashevich, I G ; Sivertseva, S A ; Shchur, S G

01 Jan 2022·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

New opportunities in the treatment of patients with multiple sclerosis (Resolution of the Council of Experts on April 23, 2022, Moscow, JSC «BIOCAD»)

Article

Author: Totolyan, N A ; Vlasov, Ya V ; Sivertseva, S A ; Khachanova, N V ; Popova, E V ; Yakushina, T I ; Spirin, N N ; Matvievskaya, O V ; Khabirov, F A ; Korsunskaya, L L ; Boyko, A N ; Zakharova, M N ; Simaniv, T O ; Goncharova, Z A

100 Deals associated with Divozilimab

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Scleroderma, Systemic	Phase 3	RU	Biocad CJSC	26 Dec 2022
Neuromyelitis Optica	Phase 3	RU	Biocad CJSC	12 Dec 2022
Multiple Sclerosis	Phase 3	RU	Biocad CJSC	05 Apr 2021
Multiple Sclerosis, Relapsing-Remitting	Phase 1	RU	Biocad CJSC	22 Feb 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ECTRIMS2019	Phase 1	Multiple Sclerosis CD20 \| FcγRllla	-	BCD-132	qmohwjgcil(umcqzrjitu) = zuayhgjodb vudhosulhh (qgnpzwjeqk ) View more	Positive	10 Sep 2019